{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:40:57Z","timestamp":1790995257867,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">There is no clinical guidance on treatment in patients with non\u2010ischemic myocardial injury and type 2 myocardial infarction (T2MI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">In a cohort of 22\u00a0589 patients in the emergency department at Karolinska University Hospital in Sweden during 2011 to 2014 we identified 3853 patients who were categorized into either type 1 myocardial infarction, T2MI, non\u2010ischemic acute and chronic myocardial injury. Data from all dispensed prescriptions within 180\u00a0days of the visit to the emergency department were obtained concerning \u03b2\u2010blockers, angiotensin\u2010converting enzyme inhibitors\/angiotensin II receptor blockers, statins, and platelet inhibitors. We estimated adjusted hazard ratios (HR) with 95% CI for all\u2010cause mortality in relationship to the number of medications (categorized into 0\u20131 [referent], 2\u20133 and 4 medications) in the groups of myocardial injury. In patients with T2MI, treatment with 2 to 3 and 4 medications was associated with a 50% and 56% lower mortality, respectively (adjusted HR [95% CI], 0.50 [0.25\u20131.01], and 0.43 [0.19\u20130.96]), while corresponding associations in patients with acute myocardial injury were 24% and 29%, respectively (adjusted HR [95% CI], 0.76 [0.59\u20130.99] and 0.71 [0.5\u20131.02]), and in patients with chronic myocardial injury 27% and 37%, respectively (adjusted HR [95% CI], 0.73 [0.58\u20130.92] and 0.63 [0.46\u20130.87]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Patients with T2MI and non\u2010ischemic acute or chronic myocardial injury are infrequently prescribed common cardiovascular medications compared with patients with type 1 myocardial infarction. However, treatment with guideline recommended drugs in patients with T2MI and acute or chronic myocardial injury is associated with a lower risk of death after adjustment for confounders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.120.017239","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T12:09:39Z","timestamp":1609243779000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment With Cardiovascular Medications: Prognosis in Patients With Myocardial Injury"],"prefix":"10.1161","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-5082","authenticated-orcid":false,"given":"Erik","family":"Kadesj\u00f6","sequence":"first","affiliation":[{"name":"Department of Medicine Karolinska Institutet Solna Sweden"},{"name":"Department of Emergency and Reparative Medicine Karolinska University Hospital Huddinge, Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Medicine Karolinska Institutet Solna Sweden"},{"name":"Department of Emergency and Reparative Medicine Karolinska University Hospital Huddinge, Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8673-9380","authenticated-orcid":false,"given":"Anwar J.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Medicine Karolinska Institutet Solna Sweden"},{"name":"Department of Emergency and Reparative Medicine Karolinska University Hospital Huddinge, Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-0263","authenticated-orcid":false,"given":"Ulrik","family":"Sartipy","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery Karolinska University Hospital Stockholm Sweden"},{"name":"Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-8347","authenticated-orcid":false,"given":"Martin J.","family":"Holzmann","sequence":"additional","affiliation":[{"name":"Department of Medicine Karolinska Institutet Solna Sweden"},{"name":"Department of Emergency and Reparative Medicine Karolinska University Hospital Huddinge, Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy462"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031806"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-315036"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.04.032"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310243"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.064"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.11.037"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.09.030"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-312409"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.11.006"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz299"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.020"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22281"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6943.1540"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04560-8"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09895-1"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs075"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.031"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042960"},{"key":"e_1_3_1_32_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383\u20131389.","journal-title":"Lancet"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.jpc60002"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021161"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.017239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:59:58Z","timestamp":1715597998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.017239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,5]]}},"alternative-id":["10.1161\/JAHA.120.017239"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.017239","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"2020-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e017239"}}